| Entry |
|
|---|
| Name |
Almotriptan malate (USP);
Axert (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C17H25N3O2S. C4H6O5
|
|---|
| Exact mass |
469.1883
|
|---|
| Mol weight |
469.5517
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG00839): | D02825<US> |
|
|---|
| Efficacy |
Antimigraine, Serotonin receptor agonist |
|---|
| Comment |
Sumatriptan derivative
Acute treatment of migraine attacks
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02C ANTIMIGRAINE PREPARATIONS
N02CC Selective serotonin (5HT1) agonists
N02CC05 Almotriptan
D02825 Almotriptan malate (USP) <US>
USP drug classification [BR:br08302]
Antimigraine Agents
Serotonin (5-HT) Receptor Agonists
Almotriptan
D02825 Almotriptan malate (USP)
Drug groups [BR:br08330]
Analgesic
DG01484 5-HT1B-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01485 5-HT1D-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01518 5-HT1B/1D-receptor agonist
DG00839 Almotriptan
D02825 Almotriptan malate
DG01943 Triptan
DG00839 Almotriptan
D02825 Almotriptan malate
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
DG02950 FMO3 substrate
DG00839 Almotriptan
D02825 Almotriptan malate
DG02917 MAO substrate
DG03178 MAOA substrate
DG00839 Almotriptan
D02825 Almotriptan malate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Serotonin
HTR1B
D02825 Almotriptan malate (USP) <US>
HTR1D
D02825 Almotriptan malate (USP) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D02825
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D02825
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02825
Drug groups [BR:br08330]
Analgesic
DG01484 5-HT1B-receptor agonist
DG00839 Almotriptan
DG01485 5-HT1D-receptor agonist
DG00839 Almotriptan
DG01518 5-HT1B/1D-receptor agonist
DG00839 Almotriptan
DG01943 Triptan
DG00839 Almotriptan
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00839 Almotriptan
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00839 Almotriptan
DG02950 FMO3 substrate
DG00839 Almotriptan
DG02917 MAO substrate
DG03178 MAOA substrate
DG00839 Almotriptan
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 32
1 O6a O 32.3870 -18.3686
2 C6a C 33.5912 -19.0639
3 C1c C 34.7956 -18.3686
4 C1b C 35.9998 -19.0639
5 C6a C 37.2041 -18.3686
6 O6a O 38.4085 -19.0639
7 O6a O 33.5912 -20.4544
8 O6a O 37.2041 -16.9782
9 O1a O 34.7956 -16.9783
10 C8y C 27.2363 -19.5213
11 C8y C 27.2363 -20.9261
12 C8y C 28.5707 -19.0999
13 C8x C 26.0422 -18.8188
14 N4x N 28.5707 -21.3475
15 C8x C 26.0422 -21.6284
16 C8x C 29.4136 -20.2236
17 C8y C 24.8481 -19.5213
18 C8x C 24.8481 -20.9261
19 C1b C 23.5839 -18.8188
20 S4a S 22.3898 -19.5213
21 O3c O 23.3732 -20.5046
22 O3c O 21.4065 -20.5046
23 N1y N 21.3979 -18.5267
24 C1x C 21.8322 -17.1908
25 C1x C 20.6958 -16.3648
26 C1x C 19.5592 -17.1903
27 C1x C 19.9930 -18.5263
28 C1b C 28.5707 -17.6998
29 C1b C 29.7716 -17.0065
30 N1c N 29.7716 -15.5905
31 C1a C 30.9879 -14.8882
32 C1a C 28.5662 -14.8946
BOND 33
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 2 7 2
7 5 8 2
8 3 9 1
9 10 11 1
10 10 12 1
11 10 13 2
12 11 14 1
13 11 15 2
14 12 16 2
15 13 17 1
16 15 18 1
17 17 19 1
18 19 20 1
19 20 21 2
20 20 22 2
21 14 16 1
22 17 18 2
23 20 23 1
24 23 24 1
25 24 25 1
26 25 26 1
27 26 27 1
28 23 27 1
29 12 28 1
30 28 29 1
31 29 30 1
32 30 31 1
33 30 32 1
|
|---|
